Clinical Relevance of Treatments for Acute Bipolar Disorder: Balancing Therapeutic and Adverse Effects

Clinical Therapeutics

Volumn 33, Issue 12, 2011, Pages

  Srivastava, Shefali ^a   Ketter, Terence A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Bipolar disorder; Likelihood to help or harm; Mood stabilizers; Number needed to harm; Number needed to treat

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; FLUOXETINE PLUS OLANZAPINE; LAMOTRIGINE; LITHIUM; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; ZIPRASIDONE;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL DECISION MAKING; DRUG EFFICACY; HUMAN; MANIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SIDE EFFECT; WEIGHT GAIN;

ACUTE DISEASE; AFFECT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT SELECTION; RESEARCH DESIGN; RISK ASSESSMENT; SLEEP; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 83455195411     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.11.020     Document Type: Review

References (42)

1. Merikangas K.R., Akiskal H.S., Angst J., et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007, 64:543-552.
2. Goodwin F.R., Jamison K. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression 2007, Oxford University Press, New York. 2nd ed.
3. Cipriani A., Barbui C., Salanti G., et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011, 378:1306-1315.
4. Yildiz A., Vieta E., Leucht S., et al. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 2011, 36:375-389.
5. Tarr G.P., Glue P., Herbison P. Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania-a systematic review and meta-analysis. J Affect Disord 2011, 134:14-19.
6. Thase M.E., Macfadden W., Weisler R.H., et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006, 26:600-609.
7. Tohen M., Vieta E., Calabrese J., et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003, 60:1079-1088.
8. Calabrese J.R., Keck P.E., Macfadden W., et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005, 162:1351-1360.
9. McElroy S.L., Weisler R.H., Chang W., et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010, 71:163-174.
10. Suppes T., Datto C., Minkwitz M., et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010, 121:106-115.
11. Young A.H., McElroy S.L., Bauer M., et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010, 71:150-162.
12. Ketter T.A., Citrome L., Wang P.W., et al. Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?. Acta Psychiatr Scand 2011, 123:175-189.
13. Kushner S.F., Khan A., Lane R., et al. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 2006, 8:15-27.
14. Thase M.E., Jonas A., Khan A., et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008, 28:13-20.
15. Sachs G.S., Ice K.S., Chappell P.B., et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011, 72:1413-1422.
16. Citrome L. Compelling or irrelevant?. Using number needed to treat can help decide. Acta Psychiatr Scand 2008, 117:412-419.
17. Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf 2009, 4:229-237.
18. Bowden C.L., Brugger A.M., Swann A.C., et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994, 271:918-924.
19. Bowden C.L., Grunze H., Mullen J., et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005, 66:111-121.
20. Bowden C.L., Swann A.C., Calabrese J.R., et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry 2006, 67:1501-1510.
21. Weisler R.H., Kalali A.H., Ketter T.A. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004, 65:478-484.
22. Weisler R.H., Keck P.E., Swann A.C., et al. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005, 66:323-330.
23. Tohen M., Sanger T.M., McElroy S.L., et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999, 156:702-709.
24. Tohen M., Jacobs T.G., Grundy S.L., et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000, 57:841-849.
25. Hirschfeld R.M., Keck P.E., Kramer M., et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004, 161:1057-1065.
26. Khanna S., Vieta E., Lyons B., et al. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry 2005, 187:229-234.
27. McIntyre R.S., Brecher M., Paulsson B., et al. Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005, 15:573-585.
28. Keck P.E., Versiani M., Potkin S., et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003, 160:741-748.
29. Potkin S.G., Keck P.E., Segal S., et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005, 25:301-310.
30. Keck P.E., Marcus R., Tourkodimitris S., et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003, 160:1651-1658.
31. Sachs G., Sanchez R., Marcus R., et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006, 20:536-546.
32. McIntyre R.S., Cohen M., Zhao J., et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009, 11:673-686.
33. McIntyre R.S., Cohen M., Zhao J., et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 2010, 122:27-38.
34. Vieta E., Nuamah I.F., Lim P., et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 2010, 12:230-243.
35. Geddes J.R., Calabrese J.R., Goodwin G.M. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009, 194:4-9.
36. Calabrese J.R., Huffman R.F., White R.L., et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008, 10:323-333.
37. Rascati K.L., Richards K.M., Ott C.A., et al. Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder. Psychiatr Serv 2011, 62:1032-1040.
38. Judd L.L., Akiskal H.S., Schettler P.J., et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002, 59:530-537.
39. Judd L.L., Akiskal H.S., Schettler P.J., et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003, 60:261-269.
40. Gao K., Ganocy S.J., Gajwani P., et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 2008, 69:302-309.
41. Gao K., Kemp D.E., Fein E., et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 2011, 72:1063-1071.
42. Citrome L. Olanzapine-fluoxetine combination for the treatment of bipolar depression. Expert Opin Pharmacother 2011, 12:2751-2758.